CHS Moves Away From Isoflavones, Sells Solgen
01 Apr 2015 --- Just three years after purchasing the Israeli soy protein firm, CHS, North America’s leading farmer-owned cooperative and a global energy, grains and foods company, announced it has sold Solgen isoflavone brand and related business to Tradichem S.L., Madrid, Spain.
Tradichem’s core business is the development and supply of pharmaceutical and nutraceutical ingredients. The transaction includes all CHS isoflavone inventory, the Solgen brand name and customer list, technology related to the product and the Solgen European Drug Master File.
“CHS recently ceased production of food-grade soy ingredients at its Ashdod, Israel, plant, and will no longer manufacture isoflavones,” said Tom Malecha, CHS vice president, Processing and Food Ingredients. “In addition to acquiring the Solgen inventory and related business assets, Tradichem will also assume all liabilities related to the former CHS isoflavone manufacturing, supply and distribution.”
Jose Angel Marañón, PhD., Tradichem executive director and director of research and development, said that Tradichem has been the CHS distributor of Solgen products for many years; making it a good fit within Tradichem’s portfolio. “We are proud to own the Solgen technology, inventory and brand and look forward to continuing to represent this outstanding product within our business,” said Marañón.
Tradichem holds exclusive distribution agreements with global pharmaceutical and nutraceutical companies based in Israel, Germany, Switzerland and the US. Tradichem has built a culture of innovation to maximize the business growth, which is driven by initiatives underway at the Tradichem Innovation Center (TIC) laboratory, a research center hosted by Parque Científico de Madrid (PCM).
